(Q51468608)

5 April 2018

title

Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. (English)

1 reference

5 April 2018

0 references

4

A Hofman

1 reference

5 April 2018

M L Becker

1

1 reference

5 April 2018

L E Visser

2

1 reference

5 April 2018

P H Trienekens

3

1 reference

5 April 2018

R H N van Schaik

5

1 reference

5 April 2018

B H Ch Stricker

6

1 reference

5 April 2018

language of work or name

English

0 references

publication date

27 June 2007

1 reference

5 April 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

5 April 2018

volume

83

1 reference

5 April 2018

issue

2

1 reference

5 April 2018

page(s)

288-292

1 reference

5 April 2018

Type 2 diabetes: principles of pathogenesis and therapy

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100273

7 January 2021

Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100273

7 January 2021

Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100273

7 January 2021

Oral Antidiabetic Agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100273

7 January 2021

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100273

7 January 2021

Clinical relevance of genetic polymorphisms in the human CYP2C9 gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100273

7 January 2021

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100273

7 January 2021

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100273

7 January 2021

Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100273

7 January 2021

Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100273

7 January 2021

Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100273

7 January 2021

The role of sulphonylureas in the management of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100273

7 January 2021

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100273

7 January 2021

The mode of action and clinical pharmacology of gliclazide: a review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100273

7 January 2021

Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100273

7 January 2021

The metabolism of gliclazide in man.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100273

7 January 2021

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100273

7 January 2021

Determinants of disease and disability in the elderly: The Rotterdam elderly study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100273

7 January 2021

Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100273

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100273

1 reference

5 April 2018

PubMed ID

17597710

1 reference

5 April 2018